}

FDA warns against use of Promise Pharmacy products

12/10/2018

The FDA is alerting healthcare professionals and patients not to use drug products intended to be sterile that were produced in an inadequately designed processing room and distributed by Promise Pharmacy due to lack of sterility assurance. FDA inspected the Promise compounding facility in November following the October 2018 recall of two Promise products, but inspectors again found insanitary conditions and poor sterile production practices. Read the FDA safety alert.

<< return to Advocacy Updates